相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway
Jamie Honeychurch et al.
BLOOD (2012)
Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients
Gilles Salles et al.
BLOOD (2012)
Aphase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies
Laurie H. Sehn et al.
BLOOD (2012)
Innate predisposition to immune escape in follicular lymphoma cells
Pauline Gravelle et al.
ONCOIMMUNOLOGY (2012)
Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies
Waleed Alduaij et al.
BLOOD (2011)
Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies
Gerhard Niederfellner et al.
BLOOD (2011)
Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells
Michaela Patz et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Novel Therapeutics for Aggressive Non-Hodgkin's Lymphoma
Daruka Mahadevan et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Direct Effect of Rituximab in B-Cell-Derived Lymphoid Neoplasias: Mechanism, Regulation, and Perspectives
Christine Bezombes et al.
MOLECULAR CANCER RESEARCH (2011)
Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101
Stephane Dalle et al.
MOLECULAR CANCER THERAPEUTICS (2011)
A role for mitochondria in NLRP3 inflammasome activation
Rongbin Zhou et al.
NATURE (2011)
Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors
Catherine Delbaldo et al.
TARGETED ONCOLOGY (2011)
Taking a good look at free radicals in the aging process
Siegfried Hekimi et al.
TRENDS IN CELL BIOLOGY (2011)
Possible misinterpretation of the mode of action of therapeutic antibodies in vitro: homotypic adhesion and flow cytometry result in artefactual direct cell death
Josee Golay et al.
BLOOD (2010)
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
Ekkehard Moessner et al.
BLOOD (2010)
HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment
Britta Weigelt et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression
Jonathan M. Irish et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Signal Transduction Inhibitor Therapy for Lymphoma
Thomas E. Witzig et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2010)
Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20
David Dayde et al.
BLOOD (2009)
Involvement of macroautophagy in the caspase-independent killing of Burkitt lymphoma cell lines by rituximab
Julie Turzanski et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Protocols to detect senescence-associated beta-galactosidase (SA-beta gal) activity, a biomarker of senescent cells in culture and in vivo
Florence Debacq-Chainiaux et al.
NATURE PROTOCOLS (2009)
Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab
M. Pickl et al.
ONCOGENE (2009)
Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation
Stephen A. Beers et al.
BLOOD (2008)
Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies
Ronald P. Taylor et al.
CURRENT OPINION IN IMMUNOLOGY (2008)
PKC zeta-mTOR pathway: a new target for rituximab therapy in follicular lymphoma
Ludivine Leseux et al.
BLOOD (2008)
Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC)
Magdalena Zietarska et al.
MOLECULAR CARCINOGENESIS (2007)
'Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions'
B. Bonavida
ONCOGENE (2007)
Syk-dependent mTOR activation in follicular lymphoma cells
Ludivine Leseux et al.
BLOOD (2006)
Three-dimensional culture of melanoma cells profoundly affects gene expression profile: A high density oligonucleotide array study
S Ghosh et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2005)
Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20m Ab) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention
AR Jazirehi et al.
ONCOGENE (2005)
Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains
C Bezombes et al.
BLOOD (2004)
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
MR Smith
ONCOGENE (2003)
Multicellular gastric cancer spheroids recapitulate growth pattern and differentiation phenotype of human gastric carcinomas
B Mayer et al.
GASTROENTEROLOGY (2001)
分享论文
